EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Pharmacological and non‐pharmacological treatments in amyotrophic lateral sclerosis: an Italian real‐world data study

Olga Paoletti, Giulia Hyeraci iD, Marco Finochietti, Maria Grazia Celani, Ilaria Bacigalupo, Niccolò Lombardi, Giada Crescioli, Marco Tuccori, Silvia Cascini, Rosa Gini, Antonio Addis, Ursula Kirchmayer und 1 weitere

European Journal of Neurology · 2024

DOI: 10.1111/ene.16470 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Neurology, 2024. Verfasst von Olga Paoletti und 12 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacoepidemiology Unit, Regional Health Agency of Tuscany, Florence, Italy. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Riluzole. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Agenzia Italiana del Farmaco, Ministero della Salute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and purpose The purpose was to describe the use patterns of pharmacological and non‐pharmacological therapies and investigate potential determinants of riluzole use in patients newly diagnosed with amyotrophic lateral sclerosis (ALS) in three Italian regions. Methods Amyotrophic lateral sclerosis patients were selected from administrative healthcare databases of Latium, Tuscany and Umbria from 1 January 2014 to 31 December 2019 based on hospital‐ and disease‐specific co‐payment exemption data. The first trace of ALS was considered the index date. Incident ALS cases were those without a trace of ALS during the 3‐year look back. Patients were described in terms of demographics, clinical characteristics and drug use at baseline, and were classified into four categories based on riluzole use in the 2 years before and 1 year after the index date: prevalent, incident, former users and non‐users. Use of symptomatic pharmacological and non‐pharmacological therapies was described across these categories during 12 months after the index date. Determinants of riluzole use were also investigated. Results and conclusions A total of 1636 ALS incident subjects were detected in the three regions, mainly aged 65–74 years. Patients were generally fragile with a high prevalence of comorbidities at baseline. Riluzole was used by 27.4% of the overall study cohort at baseline and steeply increased in the first year after the index date differently between regions (Latium 61.2%, Tuscany 85.0%, Umbria 76.5%), with about half of the subjects being incident users. In the 12 months after the index date, also symptomatic therapies increased, in riluzole users and non‐users. Determinants analysis showed that higher patient severity and complexity were associated with a lower likelihood of being treated with riluzole.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyotrophic Lateral SclerosisRiluzoleHumansItalyFemaleMaleAgedMiddle AgedNeuroprotective Agents

Stichwörter der Autor:innen

amyotrophic lateral sclerosisdeterminants of usepharmaco‐utilizationriluzole

Substanzen

RiluzoleNeuroprotective Agents

Autor:innen und Institutionen

  • Pharmacoepidemiology Unit, Regional Health Agency of Tuscany, Florence, Italy.
  • Department of Epidemiology, ASL Roma 1, SSR Lazio, Rome, Italy.
  • Neurophysiopathology, Perugia Hospital, Perugia, Italy.
  • National Center for Disease Prevention and Health Promotion, Italian National Institute of Health, Rome, Italy.
  • Section of Pharmacology and Toxicology, Department of Neurosciences, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.
  • Tuscan Regional Centre of Pharmacovigilance, Florence, Italy.

ORCID-Profile: Giulia Hyeraci

Förderung

  • Agenzia Italiana del Farmaco, Ministero della Salute

Zitieren

APA

Paoletti, O., Hyeraci, G., Finochietti, M., Celani, M. G., Bacigalupo, I., Lombardi, N., Crescioli, G., Tuccori, M., Cascini, S., Gini, R., Addis, A., Kirchmayer, U., & CAESAR study group (2024). Pharmacological and non‐pharmacological treatments in amyotrophic lateral sclerosis: an Italian real‐world data study. European Journal of Neurology. https://doi.org/10.1111/ene.16470

Vancouver

Paoletti O, Hyeraci G, Finochietti M, Celani MG, Bacigalupo I, Lombardi N, et al. Pharmacological and non‐pharmacological treatments in amyotrophic lateral sclerosis: an Italian real‐world data study. European Journal of Neurology. 2024. doi:10.1111/ene.16470

BibTeX
@article{Paoletti2024,
  author = {Paoletti, Olga and Hyeraci, Giulia and Finochietti, Marco and Celani, Maria Grazia and Bacigalupo, Ilaria and Lombardi, Niccolò and Crescioli, Giada and Tuccori, Marco and Cascini, Silvia and Gini, Rosa and Addis, Antonio and Kirchmayer, Ursula and CAESAR study group, CAESAR study group},
  title = {Pharmacological and non‐pharmacological treatments in amyotrophic lateral sclerosis: an Italian real‐world data study},
  journal = {European Journal of Neurology},
  year = {2024},
  doi = {10.1111/ene.16470}
}
Kostenlos starten →